Send a text

In today’s episode of the Psychedelic Therapy Frontiers podcast we discuss a paper recently published in JAMA (Journal of the American Medical Association) entitled, “Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.” This is a report on the results from Mind Medicine’s phase 2b clinical trial that Reid and I both had the pleasure of working on at Numinus Network’s clinical trial site, Cedar Clinical Research. We discuss what GAD is, a brief history of LSD, why LSD might be helpful for anxiety, the study design, the difference between session monitoring vs psychedelic-assisted therapy, and more. Near the end of the episode we briefly discuss another recently published paper, this one on psilocybin and how the phenomenology of a psychedelic experience might contribute to positive psychological changes.
For those of you who are new to the show, welcome! Psychedelic Therapy Frontiers is brought to you by Numinus Network and is hosted by Dr. Steve Thayer and Dr. Reid Robison.

https://jamanetwork.com/journals/jama/article-abstract/2838505

https://link.springer.com/article/10.1007/s43440-025-00742-5

Learn more about our podcast at https://numinusnetwork.com/learn/podcast/
Learn more about psychedelic therapy training opportunities at https://numinusnetwork.com/training/
Learn more about our clinical trials at https://www.numinusnetwork.com/research
Learn more about Numinus at https://numinusnetwork.com/

Email us at ptfpodcast@numinus.com

Follow us on Instagram:
https://www.instagram.com/drstevethayer/
https://www.instagram.com/innerspacedoctor/
https://www.instagram.com/numinushealth/

Polska armia w 2026: jesteśmy gotowi czy wciąż nadrabiamy 30 lat zaniedbań? Damian Ratka, Defence24

Układ Otwarty. Igor Janke zaprasza

Model współpracy państwo–przemysł wzorem USA

The AI-powered Podcast Player